ジャーナル: Science / 年: 2021 タイトル: Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape. 著者: Paul-Albert Koenig / Hrishikesh Das / Hejun Liu / Beate M Kümmerer / Florian N Gohr / Lea-Marie Jenster / Lisa D J Schiffelers / Yonas M Tesfamariam / Miki Uchima / Jennifer D Wuerth / Karl ...著者: Paul-Albert Koenig / Hrishikesh Das / Hejun Liu / Beate M Kümmerer / Florian N Gohr / Lea-Marie Jenster / Lisa D J Schiffelers / Yonas M Tesfamariam / Miki Uchima / Jennifer D Wuerth / Karl Gatterdam / Natalia Ruetalo / Maria H Christensen / Caroline I Fandrey / Sabine Normann / Jan M P Tödtmann / Steffen Pritzl / Leo Hanke / Jannik Boos / Meng Yuan / Xueyong Zhu / Jonathan L Schmid-Burgk / Hiroki Kato / Michael Schindler / Ian A Wilson / Matthias Geyer / Kerstin U Ludwig / B Martin Hällberg / Nicholas C Wu / Florian I Schmidt / 要旨: The pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to spread, with devastating consequences. For passive immunization efforts, nanobodies have size and cost ...The pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to spread, with devastating consequences. For passive immunization efforts, nanobodies have size and cost advantages over conventional antibodies. In this study, we generated four neutralizing nanobodies that target the receptor binding domain of the SARS-CoV-2 spike protein. We used x-ray crystallography and cryo-electron microscopy to define two distinct binding epitopes. On the basis of these structures, we engineered multivalent nanobodies with more than 100 times the neutralizing activity of monovalent nanobodies. Biparatopic nanobody fusions suppressed the emergence of escape mutants. Several nanobody constructs neutralized through receptor binding competition, whereas other monovalent and biparatopic nanobodies triggered aberrant activation of the spike fusion machinery. These premature conformational changes in the spike protein forestalled productive fusion and rendered the virions noninfectious.
履歴
登録
2020年11月24日
登録サイト: PDBE / 処理サイト: PDBE
改定 1.0
2021年4月28日
Provider: repository / タイプ: Initial release
改定 1.0
2021年4月28日
Data content type: EM metadata / Data content type: EM metadata / Provider: repository / タイプ: Initial release
改定 1.0
2021年4月28日
Data content type: FSC / Data content type: FSC / Provider: repository / タイプ: Initial release
改定 1.0
2021年4月28日
Data content type: Half map / Part number: 1 / Data content type: Half map / Provider: repository / タイプ: Initial release
改定 1.0
2021年4月28日
Data content type: Half map / Part number: 2 / Data content type: Half map / Provider: repository / タイプ: Initial release
改定 1.0
2021年4月28日
Data content type: Image / Data content type: Image / Provider: repository / タイプ: Initial release
改定 1.0
2021年4月28日
Data content type: Primary map / Data content type: Primary map / Provider: repository / タイプ: Initial release
改定 1.0
2021年4月28日
Data content type: FSC / Data content type: FSC / Provider: repository / タイプ: Initial release
改定 1.0
2021年4月28日
Data content type: Half map / Part number: 1 / Data content type: Half map / Provider: repository / タイプ: Initial release
改定 1.0
2021年4月28日
Data content type: Half map / Part number: 2 / Data content type: Half map / Provider: repository / タイプ: Initial release
改定 1.0
2021年4月28日
Data content type: Image / Data content type: Image / Provider: repository / タイプ: Initial release
改定 1.0
2021年4月28日
Data content type: Primary map / Data content type: Primary map / Provider: repository / タイプ: Initial release
Data content type: EM metadata / Data content type: EM metadata / EM metadata / Group: Data processing / Experimental summary / Data content type: EM metadata / EM metadata / カテゴリ: em_admin / em_software / Data content type: EM metadata / EM metadata / Item: _em_admin.last_update / _em_software.name
A: Spike glycoprotein B: Spike glycoprotein C: Spike glycoprotein D: Nanobody against SARS-CoV-2 VHH E E: Nanobody against spike glycoprotein VHH V F: Nanobody against SARS-CoV-2 VHH E G: Nanobody against spike glycoprotein VHH V H: Nanobody against SARS-CoV-2 VHH E I: Nanobody against spike glycoprotein VHH V ヘテロ分子